Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:REGN
CUSIP: 75886F10
Web: www.regeneron.com

Capitalization:

Market Cap: $45.75 billion
Outstanding Shares: 106,033,000

Average Prices:

50 Day Moving Avg: $468.97
200 Day Moving Avg: $447.18
52 Week Range: $325.35 - $543.55

P/E:

Trailing P/E Ratio: 43.28
Foreward P/E Ratio: 25.93
P/E Growth: 1.61

Sales & Book Value:

Annual Revenue: $5.24 billion
Price / Sales: 8.73
Book Value: $52.07 per share
Price / Book: 8.29

Profitability:

EBIDTA: $1.82 billion
Net Margins: 22.05%
Return on Equity: 25.58%
Return on Assets: 16.63%

Debt:

Debt-to-Equity Ratio: 0.13%
Current Ratio: 3.75%
Quick Ratio: 3.21%

Misc:

Average Volume: 845,638 shs.
Beta: 1.65
Short Ratio: 3.33

Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.67 by $1.50. The business earned $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm's quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.82 EPS. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

25 brokerages have issued 1 year price targets for Regeneron Pharmaceuticals' stock. Their predictions range from $345.00 to $605.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $492.82 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

1. According to Zacks Investment Research, "Regeneron’s second-quarter results were impressive as both earnings and sales beat estimates on the back of strong Eylea sales which grabbed additional market share. Regeneron’s key growth driver, Eylea, continues to drive revenues and the company is expanding the drug's label for additional indications. The increase in guidance was also encouraging. The FDA’s approval of Dupixent was a major boost to the company’s portfolio and the company is working to expand its label. A potential approval of the drug in the EU in the second half will further boost sales. Further, the approval of Kevzara (sarilumab) for the treatment of moderately-to-severely active rheumatoid arthritis both in the U.S.and EU has boosted the company’s portfolio. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress." (8/9/2017)
2. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
3. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
4. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), Axovant Sciences Ltd (AXON), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO) and China Biologic Products (CBPO).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

P. Roy Vagelos M.D., Chairman of the Board
Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
Neil Stahl Ph.D., Executive Vice President - Research and Development
Robert J. Terifay, Executive Vice President - Commercial
Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
Peter Powchik M.D., Senior Vice President - Clinical Development
George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (6.67%), Capital World Investors (6.54%), BlackRock Inc. (5.86%), Vanguard Group Inc. (4.99%), State Street Corp (3.10%) and Artisan Partners Limited Partnership (1.86%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Southpoint Capital Advisors LP, Capital World Investors, Bank of New York Mellon Corp, State Street Corp, Manning & Napier Advisors LLC, BB Biotech AG, Ameriprise Financial Inc. and Rockefeller Financial Services Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, FMR LLC, TIAA CREF Investment Management LLC, PointState Capital LP, Vanguard Group Inc., Teachers Advisors LLC and Polen Capital Management LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $431.44.

MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		967 (Vote Outperform)
Underperform Votes:		734 (Vote Underperform)
Total Votes:		1,701

MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Sell Rating, 13 Hold Ratings, 11 Buy Ratings
Consensus Rating:	Hold (Score: 2.40)
Consensus Price Target:	$492.82 (14.23% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/14/2017	Royal Bank Of Canada	Initiated Coverage	Sector Perform -> Sector Perform	$475.00	Medium
9/11/2017	Canaccord Genuity	Reiterated Rating	Buy	$522.00	Low
9/11/2017	Credit Suisse Group	Reiterated Rating	Buy	$485.00	Low
9/8/2017	Robert W. Baird	Reiterated Rating	Sell	$408.00	Low
9/7/2017	Citigroup Inc.	Reiterated Rating	Buy	$575.00	Low
9/6/2017	Raymond James Financial, Inc.	Reiterated Rating	Outperform -> Outperform	$566.00	Low
8/23/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$450.00	Low
8/16/2017	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$605.00	Medium
8/15/2017	J P Morgan Chase & Co	Reiterated Rating	Hold		Low
8/15/2017	Leerink Swann	Reiterated Rating	Outperform -> Positive	$580.00 -> $552.00	Low
8/9/2017	Jefferies Group LLC	Reiterated Rating	Hold	$418.00 -> $471.00	Low
8/9/2017	Goldman Sachs Group, Inc. (The)	Reiterated Rating	Neutral	$469.00 -> $472.00	Low
8/3/2017	BMO Capital Markets	Set Price Target	Hold	$491.00	Low
8/1/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$557.00	High
7/22/2017	Barclays PLC	Reiterated Rating	Equal Weight	$400.00 -> $450.00	Low
7/21/2017	Bank of America Corporation	Reiterated Rating	Buy	$589.00 -> $593.00	Low
6/30/2017	BTIG Research	Reiterated Rating	Buy -> Buy	$480.00 -> $540.00	High
6/26/2017	Sanford C. Bernstein	Downgrade	Outperform -> Market Perform	$410.00 -> $480.00	Low
6/14/2017	Oppenheimer Holdings, Inc.	Reiterated Rating	Hold		Low
5/15/2017	Cowen and Company	Reiterated Rating	Hold	$380.00	Low
3/17/2017	CIBC	Initiated Coverage	Market Perform -> Market Perform		Low
1/10/2017	Wells Fargo & Company	Reiterated Rating	Market Perform		N/A
1/6/2017	Chardan Capital	Lower Price Target	Neutral	$350.00 -> $345.00	N/A
12/28/2016	Argus	Reiterated Rating	Buy	$450.00	N/A
10/28/2016	Roth Capital	Set Price Target	Buy	$520.00	N/A
8/5/2016	Brean Capital	Reiterated Rating	Buy	$489.00	N/A
3/17/2016	SunTrust Banks, Inc.	Lower Price Target	Neutral	$450.00 -> $410.00	N/A
3/15/2016	Gabelli	Initiated Coverage	Buy	$574.00	N/A

(Data available from 9/22/2015 forward)

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/2/2017		$3.83					N/A
8/3/2017	Q2 2017	$2.67	$4.17	$1.36 billion	$1.47 billion	View	Listen
5/4/2017	Q1 2017	$2.50	$2.92	$1.30 billion	$1.32 billion	View	Listen
2/9/2017	Q4 2016	$3.03	$3.04	$1.30 billion	$1.23 billion	View	Listen
11/4/2016	Q316	$2.73	$3.13	$1.29 billion	$1.22 billion	View	N/A
8/4/2016	Q216	$2.65	$2.82	$1.24 billion	$1.21 billion	View	N/A
5/5/2016	Q116	$2.58	$2.57	$1.18 billion	$1.20 billion	View	N/A
2/9/2016	Q415	$3.40	$2.83	$1.17 billion	$1.10 billion	View	Listen
11/4/2015	Q315	$2.62	$3.47	$1.05 billion	$1.14 billion	View	Listen
8/4/2015	Q215	$2.77	$2.89	$887.03 million	$999.00 million	View	Listen
5/7/2015	Q115	$2.50	$2.88	$820.30 million	$870.00 million	View	N/A
2/10/2015	Q414	$2.78	$2.79	$775.42 million	$802.00 million	View	N/A
11/4/2014	Q314	$2.57	$2.52	$733.04 million	$726.00 million	View	N/A
8/5/2014	Q214	$2.30	$2.47	$647.99 million	$666.00 million	View	N/A
5/8/2014	Q114	$0.94	$0.58	$609.04 million	$626.00 million	View	N/A
2/11/2014	Q413	$0.97	$2.24	$579.17 million	$610.00 million	View	N/A
11/5/2013	Q313	$0.92	$2.40	$501.93 million	$597.00 million	View	N/A
8/6/2013	Q2 2013	$0.92	$1.73	$470.63 million	$458.00 million	View	N/A
5/3/2013	Q1 2013	$1.46	$1.78	$424.26 million	$440.00 million	View	N/A
2/14/2013	Q4 2012	$1.11	$1.47	$392.64 million	$415.00 million	View	N/A
10/24/2012		$1.14	$1.89			View	N/A
7/25/2012		$0.45	$0.90			View	N/A
4/26/2012		($0.33)	$0.37			View	N/A
2/13/2012		($0.60)	($0.37)			View	N/A
7/28/2011		($0.40)	($0.69)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Current Year EPS Consensus Estimate: $14.89 EPS
Next Year EPS Consensus Estimate: $16.64 EPS

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 67.94%

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/6/2017	Robert E Landry	SVP	Sell	663	$498.60	$330,571.80
9/5/2017	Robert E Landry	CFO	Sell	189	$501.06	$94,700.34
8/31/2017	Robert E Landry	SVP	Sell	427	$493.43	$210,694.61
8/25/2017	Sanofi	Major Shareholder	Buy	72,378	$481.36	$34,839,874.08
8/24/2017	Sanofi	Major Shareholder	Buy	166,415	$480.93	$80,033,965.95
8/23/2017	Robert E Landry	SVP	Sell	468	$476.45	$222,978.60
8/22/2017	P Roy Vagelos	Chairman	Sell	56,213	$474.48	$26,671,944.24
8/18/2017	P Roy Vagelos	Chairman	Sell	15,191	$470.15	$7,142,048.65
8/17/2017	P Roy Vagelos	Chairman	Sell	1,305	$470.00	$613,350.00
8/16/2017	P Roy Vagelos	Chairman	Sell	10,986	$470.17	$5,165,287.62
8/8/2017	Robert E Landry	SVP	Sell	526	$472.19	$248,371.94
6/22/2017	Michael S Aberman	SVP	Sell	2,269	$532.42	$1,208,060.98
6/22/2017	Neil Stahl	EVP	Sell	8,306	$532.55	$4,423,360.30
6/20/2017	Michael S Brown	Director	Sell	3,000	$500.00	$1,500,000.00
6/16/2017	Robert J Terifay	EVP	Sell	21,147	$468.19	$9,900,813.93
6/15/2017	Neil Stahl	EVP	Sell	8,567	$468.45	$4,013,211.15
6/9/2017	Joseph L Goldstein	Director	Sell	1,000	$482.55	$482,550.00
6/2/2017	Neil Stahl	EVP	Sell	2,812	$479.49	$1,348,325.88
6/2/2017	Sanofi	Major Shareholder	Buy	136,050	$478.17	$65,055,028.50
5/25/2017	P Roy Vagelos	Chairman	Sell	9,295	$458.14	$4,258,411.30
5/12/2017	Michael S Brown	Director	Sell	3,000	$450.00	$1,350,000.00
3/29/2017	Michael S Brown	Director	Sell	1,000	$400.00	$400,000.00
1/11/2017	Sanofi	Major Shareholder	Buy	87,298	$369.71	$32,274,943.58
12/12/2016	Charles A Baker	Director	Sell	3,000	$392.02	$1,176,060.00
11/15/2016	Arthur F Ryan	Director	Sell	2,000	$429.34	$858,680.00
11/14/2016	Joseph L Goldstein	Director	Sell	2,125	$450.00	$956,250.00
7/29/2016	Joseph L Goldstein	Director	Sell	2,125	$425.00	$903,125.00
6/14/2016	Sanofi	Major Shareholder	Buy	64,731	$363.86	$23,553,021.66
5/24/2016	Arthur F Ryan	Director	Sell	1,000	$396.64	$396,640.00
5/18/2016	Plew Daniel P Van	EVP	Sell	4,413	$385.77	$1,702,403.01
4/6/2016	Joseph L Goldstein	Director	Sell	2,000	$425.00	$850,000.00
3/21/2016	Joseph L Goldstein	Director	Sell	2,000	$375.00	$750,000.00
2/17/2016	Sanofi	Major Shareholder	Buy	161,157	$392.46	$63,247,676.22
1/12/2016	Sanofi	Major Shareholder	Buy	83,938	$465.04	$39,034,527.52
12/29/2015	Douglas S. Mccorkle	VP	Sell	3,954	$552.08	$2,182,924.32
12/10/2015	Michael S. Brown	Director	Sell	3,000	$546.45	$1,639,350.00
12/2/2015	George Yancopoulos	insider	Sell	43,348	$549.03	$23,799,352.44
11/18/2015	P Roy Vagelos	Chairman	Sell	17,240	$587.90	$10,135,396.00
11/10/2015	Plew Daniel P. Van	SVP	Sell	5,123	$554.85	$2,842,496.55
11/9/2015	Neil Stahl	EVP	Sell	42,101	$561.45	$23,637,606.45
11/3/2015	P Roy Vagelos	Chairman	Sell	17,242	$580.19	$10,003,635.98
11/2/2015	George Yancopoulos	insider	Sell	43,348	$571.61	$24,778,150.28
10/6/2015	Sanofi	Major Shareholder	Buy	80,538	$459.71	$37,024,123.98
9/23/2015	Sanofi	Major Shareholder	Buy	147,209	$534.67	$78,708,236.03
9/21/2015	Michael S. Brown	Director	Sell	3,000	$551.55	$1,654,650.00
9/17/2015	Charles A. Baker	Director	Sell	5,000	$550.00	$2,750,000.00
8/14/2015	Peter Powchik	SVP	Sell	23,485	$573.38	$13,465,829.30
7/15/2015	Joseph L Goldstein	Director	Sell	2,000	$550.00	$1,100,000.00
6/22/2015	Joseph L Goldstein	Director	Sell	2,000	$526.85	$1,053,700.00
5/27/2015	Robert Alexander Ingram	Director	Sell	1,379	$513.39	$707,964.81
5/26/2015	Plew Daniel P Van	SVP	Sell	18,370	$508.42	$9,339,675.40
5/22/2015	Douglas S Mccorkle	VP	Sell	13,000	$515.60	$6,702,800.00
5/22/2015	Joseph L Goldstein	Director	Sell	4,000	$514.28	$2,057,120.00
5/15/2015	Michael S Brown	Director	Sell	5,000	$495.00	$2,475,000.00
3/25/2015	Charles A Baker	Director	Sell	5,000	$454.96	$2,274,800.00
3/24/2015	Michael S Aberman	SVP	Sell	4,843	$478.99	$2,319,748.57
3/18/2015	Michael S Aberman	SVP	Sell	3,442	$465.00	$1,600,530.00
3/17/2015	Robert J Terifay	SVP	Sell	10,993	$451.01	$4,957,952.93
3/16/2015	Joseph J Larosa	SVP	Sell	18,311	$450.00	$8,239,950.00
2/27/2015	Douglas S Mccorkle	VP	Sell	3,000	$416.24	$1,248,720.00
2/26/2015	Marc Tessier-Lavigne	Director	Sell	3,000	$421.95	$1,265,850.00
2/24/2015	Robert J Terifay	SVP	Sell	11,173	$423.67	$4,733,664.91
2/23/2015	Plew Daniel P Van	SVP	Sell	9,431	$427.82	$4,034,770.42
2/20/2015	Joseph L Goldstein	Director	Sell	5,000	$423.65	$2,118,250.00
2/17/2015	Michael S Aberman	SVP	Sell	3,692	$404.46	$1,493,266.32
1/2/2015	Leonard S Schleifer	CEO	Sell	1,500	$410.58	$615,870.00
1/2/2015	Peter Powchik	SVP	Sell	10,822	$414.08	$4,481,173.76
12/24/2014	Sanofi	Major Shareholder	Buy	201,459	$393.21	$79,215,693.39
12/16/2014	Douglas S Mccorkle	VP	Sell	8,486	$410.15	$3,480,532.90
11/24/2014	Alfred G Gilman	Director	Sell	40,000	$408.44	$16,337,600.00
11/24/2014	Neil Stahl	SVP	Sell	5,307	$412.93	$2,191,419.51
11/18/2014	Robert J Terifay	SVP	Sell	22,362	$405.79	$9,074,275.98
11/13/2014	Plew Daniel P Van	SVP	Sell	8,575	$399.34	$3,424,340.50
11/12/2014	Joseph L Goldstein	Director	Sell	5,000	$398.31	$1,991,550.00
11/12/2014	Leonard S Schleifer	CEO	Sell	45,817	$400.30	$18,340,545.10
10/28/2014	Leonard S Schleifer	CEO	Sell	69,112	$404.01	$27,921,939.12
10/24/2014	Michael S Brown	Director	Sell	5,000	$399.00	$1,995,000.00
10/24/2014	Murray A Goldberg	SVP	Sell	26,788	$400.70	$10,733,951.60
9/16/2014	Sanofi	Major Shareholder	Buy	31,717	$349.26	$11,077,479.42
9/15/2014	Sanofi	Major Shareholder	Buy	140,632	$345.15	$48,539,134.80
9/10/2014	P Roy Vagelos	Chairman	Sell	10,328	$350.07	$3,615,522.96
8/27/2014	Joseph L Goldstein	Director	Sell	2,000	$350.31	$700,620.00
8/19/2014	Michael S Aberman	VP	Sell	3,611	$350.00	$1,263,850.00
8/18/2014	Douglas S Mccorkle	VP	Sell	5,875	$353.00	$2,073,875.00
8/15/2014	Michael S Brown	Director	Sell	3,000	$349.20	$1,047,600.00
8/14/2014	Joseph L Goldstein	Director	Sell	2,000	$347.65	$695,300.00
8/13/2014	P Roy Vagelos	Chairman	Sell	8,028	$340.01	$2,729,600.28
8/11/2014	Neil Stahl	SVP	Sell	11,646	$339.96	$3,959,174.16
8/11/2014	P Roy Vagelos	Chairman	Sell	11,972	$340.11	$4,071,796.92
8/8/2014	Neil Stahl	SVP	Sell	2,841	$340.60	$967,644.60
8/7/2014	Plew Daniel P Van	SVP	Sell	6,806	$338.37	$2,302,946.22
8/6/2014	Joseph L Goldstein	Director	Sell	2,000	$331.20	$662,400.00
7/15/2014	Sanofi	Major Shareholder	Buy	129,100	$314.92	$40,656,172.00
7/14/2014	Sanofi	Major Shareholder	Buy	300,000	$316.80	$95,040,000.00
7/10/2014	Sanofi	Major Shareholder	Buy	175,000	$311.08	$54,439,000.00
7/9/2014	Sanofi	Major Shareholder	Buy	348,000	$309.76	$107,796,480.00
7/7/2014	Sanofi	Major Shareholder	Buy	356,700	$312.37	$111,422,379.00
7/2/2014	Sanofi	Major Shareholder	Buy	212,400	$307.25	$65,259,900.00
7/1/2014	Sanofi	Major Shareholder	Buy	212,400	$300.20	$63,762,480.00
6/30/2014	Sanofi	Major Shareholder	Buy	262,400	$281.17	$73,779,008.00
5/23/2014	Plew Daniel Van	SVP	Sell	5,369	$295.93	$1,588,848.17
5/19/2014	Sanofi	major shareholder	Buy	190,751	$300.04	$57,232,930.04
3/28/2014	Sanofi	major shareholder	Buy	306,945	$306.73	$94,149,239.85
3/27/2014	Sanofi	major shareholder	Buy	306,945	$311.01	$95,462,964.45
3/24/2014	Charles Baker	Director	Sell	15,000	$302.67	$4,540,050.00
3/24/2014	Sanofi	major shareholder	Buy	306,945	$307.91	$94,511,434.95
3/21/2014	Sanofi	major shareholder	Buy	305,115	$321.22	$98,009,040.30
3/20/2014	Sanofi	major shareholder	Buy	67,703	$328.33	$22,228,925.99
3/17/2014	Michael Brown	Director	Sell	2,000	$334.29	$668,580.00
3/17/2014	Sanofi	major shareholder	Buy	115,711	$328.46	$38,006,435.06
3/12/2014	Sanofi	major shareholder	Buy	220,995	$334.69	$73,964,816.55
3/11/2014	Sanofi	major shareholder	Buy	380,532	$330.41	$125,731,578.12
3/7/2014	Sanofi	major shareholder	Buy	150,277	$328.72	$49,399,055.44
3/3/2014	Sanofi	major shareholder	Buy	251,594	$338.12	$85,068,963.28
2/27/2014	Michael Brown	Director	Sell	1,000	$335.00	$335,000.00
2/25/2014	Joseph Goldstein	Director	Sell	1,000	$338.86	$338,860.00
2/25/2014	Murray Goldberg	SVP	Sell	11,871	$339.55	$4,030,798.05
2/21/2014	Alfred Gilman	Director	Sell	5,000	$340.00	$1,700,000.00
2/21/2014	Murray Goldberg	SVP	Sell	21,258	$336.51	$7,153,529.58
2/20/2014	Joseph Goldstein	Director	Sell	1,000	$326.99	$326,990.00
2/18/2014	Michael Aberman	VP	Sell	3,648	$331.42	$1,209,020.16
2/18/2014	Robert Terifay	SVP	Sell	12,865	$332.68	$4,279,928.20
2/13/2014	Neil Stahl	SVP	Sell	22,612	$318.82	$7,209,157.84
2/12/2014	George Yancopoulos	Insider	Sell	88,987	$320.33	$28,505,205.71
2/12/2014	Joseph Goldstein	Director	Sell	1,000	$320.62	$320,620.00
2/11/2014	Alfred Gilman	Director	Sell	5,000	$320.00	$1,600,000.00
2/11/2014	Douglas Mccorkle	VP	Sell	5,819	$325.00	$1,891,175.00
2/11/2014	P Roy Vagelos	Chairman	Sell	11,475	$325.10	$3,730,522.50
2/7/2014	Sanofi	major shareholder	Buy	168,511	$286.78	$48,325,584.58
2/5/2014	Sanofi	major shareholder	Buy	397,264	$284.12	$112,870,647.68
2/3/2014	Sanofi	major shareholder	Buy	208,972	$283.78	$59,302,074.16
1/28/2014	Sanofi	major shareholder	Buy	157,920	$275.90	$43,570,128.00
1/14/2014	Alfred Gilman	Director	Sell	5,000	$300.00	$1,500,000.00
1/14/2014	Douglas Mccorkle	VP	Sell	4,000	$290.00	$1,160,000.00
1/2/2014	Peter Powchik	SVP	Sell	20,668	$274.77	$5,678,946.36
12/20/2013	Peter Powchik	SVP	Sell	9,133	$270.21	$2,467,827.93
11/26/2013	George Sing	Director	Sell	10,000	$295.00	$2,950,000.00
11/6/2013	Joseph Goldstein	Director	Sell	1,000	$300.74	$300,740.00
9/19/2013	Leonard Schleifer	CEO	Sell	102,949	$302.67	$31,159,573.83
9/19/2013	P Roy Vagelos	Chairman	Sell	145,356	$302.86	$44,022,518.16
9/18/2013	Plew Daniel Van	SVP	Sell	23,977	$303.17	$7,269,107.09
9/18/2013	William Roberts	VP	Sell	15,000	$304.00	$4,560,000.00
9/9/2013	Leonard S Schleifer	CEO	Sell	5,000	$275.47	$1,377,350.00
8/23/2013	Joseph Goldstein	Director	Sell	1,000	$238.29	$238,290.00
6/10/2013	Charles A Baker	Director	Sell	15,000	$251.84	$3,777,600.00
5/31/2013	Arthur F Ryan	Director	Sell	2,500	$249.55	$623,875.00
5/28/2013	Joseph L Goldstein	Director	Sell	4,000	$252.20	$1,008,800.00
5/21/2013	Murray A Goldberg	CFO	Sell	66,835	$259.74	$17,359,722.90
5/17/2013	Michael S Brown	Director	Sell	15,000	$275.19	$4,127,850.00
5/14/2013	Michael S Aberman	VP	Sell	5,529	$279.61	$1,545,963.69
5/13/2013	Neil Stahl	SVP	Sell	23,038	$276.88	$6,378,761.44
5/10/2013	George L Sing	Director	Sell	5,000	$270.00	$1,350,000.00
5/8/2013	Robert J Terifay	SVP	Sell	8,231	$261.23	$2,150,184.13
5/6/2013	P Roy Vagelos	Chairman	Sell	12,018	$263.15	$3,162,536.70
11/27/2012	P Roy Vagelos	Chairman	Sell	64,753	$175.22	$11,346,020.66
11/26/2012	Charles A Baker	Director	Sell	15,000	$173.87	$2,608,050.00
11/14/2012	Michael S Brown	Director	Sell	7,000	$147.03	$1,029,210.00
11/1/2012	Arthur F Ryan	Director	Sell	10,000	$145.57	$1,455,700.00
9/6/2012	Charles A Baker	Director	Sell	15,000	$150.00	$2,250,000.00
8/23/2012	George L Sing	Director	Sell	10,000	$140.50	$1,405,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN) Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)

Source:

Date	Headline
	Regeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $500.00 by Analysts at UBS AG www.americanbankingnews.com - September 21 at 3:44 PM
	Regeneron's Biggest Long-Term Opportunity - Barron's www.barrons.com - September 20 at 8:19 AM
	Regeneron - Diversification Efforts Could Soon Yield Results - Seeking Alpha seekingalpha.com - September 20 at 8:19 AM
	[$$] Regeneron's Biggest Long-Term Opportunity finance.yahoo.com - September 20 at 8:19 AM
	Canaccord Genuity Reaffirms Buy Rating for Regeneron Pharmaceuticals, Inc. (REGN) www.americanbankingnews.com - September 17 at 10:22 PM
	Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis finance.yahoo.com - September 17 at 7:20 AM
	Regeneron Pharmaceuticals, Inc. (REGN) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - September 16 at 8:40 PM
	Analysts’ Recommendations for Regeneron in September 2017 finance.yahoo.com - September 15 at 11:18 PM
	Regeneron Is Focused on Increasing Awareness for Eylea in 2017 finance.yahoo.com - September 15 at 11:18 PM
	Eylea Leads the Retinal Diseases Sector finance.yahoo.com - September 15 at 11:18 PM
	Swoop In To Pick Up Regeneron This Month - Seeking Alpha seekingalpha.com - September 15 at 8:07 AM
	Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis finance.yahoo.com - September 15 at 8:07 AM
	Regeneron Pharmaceuticals, Inc. (REGN) Now Covered by Analysts at Royal Bank Of Canada www.americanbankingnews.com - September 14 at 5:26 PM
	Regeneron's Delivery Isn't Matching the Hype finance.yahoo.com - September 14 at 1:49 AM
	Oversold Conditions For Regeneron Pharmaceuticals (REGN) - Nasdaq www.nasdaq.com - September 13 at 8:43 PM
	Regeneron's Frustrating Month: Analysis And Commentary - Seeking Alpha seekingalpha.com - September 13 at 8:18 AM
	Sanofi indicates dupilumab could be used to treat nasal polyps finance.yahoo.com - September 13 at 8:18 AM
	Regeneron's Dupixent Takes Another Step Toward Blockbuster Status finance.yahoo.com - September 13 at 8:18 AM
	5 Things Regeneron's CEO Said as the Biotech Stock Sank finance.yahoo.com - September 12 at 9:07 AM
	Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Credit Suisse Group www.americanbankingnews.com - September 11 at 3:50 PM
	Sanofi: Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial www.finanznachrichten.de - September 11 at 6:20 AM
	Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial www.nasdaq.com - September 11 at 6:20 AM
	Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma finance.yahoo.com - September 11 at 6:20 AM
	Sanofi and Regeneron announce positive dupilumab topline results finance.yahoo.com - September 11 at 6:20 AM
	Sanofi and Regeneron score asthma hit with dupilumab finance.yahoo.com - September 11 at 6:20 AM
	Regeneron Pharmaceuticals' (REGN) Buy Rating Reaffirmed at Citigroup Inc. www.americanbankingnews.com - September 10 at 12:34 AM
	Robert W. Baird Reiterates "Sell" Rating for Regeneron Pharmaceuticals Inc (REGN) www.americanbankingnews.com - September 9 at 5:38 PM
	Regeneron's Cemiplimab Gains Breakthrough Therapy Status finance.yahoo.com - September 9 at 7:49 AM
	Regeneron Pharmaceuticals, Inc. (REGN) Expected to Post Quarterly Sales of $1.46 Billion www.americanbankingnews.com - September 9 at 1:30 AM
	Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma www.nasdaq.com - September 8 at 7:36 AM
	Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma finance.yahoo.com - September 8 at 7:35 AM
	Why Regeneron (REGN) Could Be Positioned for a Surge finance.yahoo.com - September 7 at 8:15 AM
	Regeneron Pharmaceuticals Ready to Make All-Time Highs finance.yahoo.com - September 7 at 8:15 AM
	VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug finance.yahoo.com - September 7 at 8:15 AM
	Robert E. Landry Sells 189 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock www.americanbankingnews.com - September 6 at 9:16 PM
	Robert E. Landry Sells 663 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock www.americanbankingnews.com - September 6 at 8:28 PM
	Raymond James Financial, Inc. Reaffirms "Outperform" Rating for Regeneron Pharmaceuticals, Inc. (REGN) www.americanbankingnews.com - September 6 at 10:49 AM
	Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : September 1, 2017 finance.yahoo.com - September 2 at 8:01 AM
	Robert E. Landry Sells 427 Shares of Regeneron Pharmaceuticals, Inc. (REGN) Stock www.americanbankingnews.com - September 1 at 8:04 PM
	Regeneron Pharmaceuticals Witnessed Solid Growth in 2Q17 finance.yahoo.com - August 30 at 8:30 AM
	How Did Regeneron’s Eylea and Praluent Perform in 2Q17? finance.yahoo.com - August 30 at 8:30 AM
	Dupixent and Kevzara: Regeneron’s Long-Term Growth Drivers? finance.yahoo.com - August 30 at 8:30 AM
	Regeneron Pharmaceuticals, Inc. (REGN) Major Shareholder Sanofi Purchases 72,378 Shares www.americanbankingnews.com - August 29 at 7:16 PM
	Regeneron Pharmaceuticals, Inc. (REGN) Rating Increased to Strong-Buy at BidaskClub www.americanbankingnews.com - August 27 at 6:12 PM
	Novartis hopeful for novel heart drug, despite 'modest' benefit finance.yahoo.com - August 27 at 6:23 AM
	Insider Buying: Regeneron Pharmaceuticals, Inc. (REGN) Major Shareholder Purchases 166,415 Shares of Stock www.americanbankingnews.com - August 25 at 7:22 PM
	Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 finance.yahoo.com - August 25 at 10:42 AM
	Regeneron Pharmaceuticals, Inc. (REGN) SVP Robert E. Landry Sells 468 Shares www.americanbankingnews.com - August 24 at 7:34 PM
	Insider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Chairman Sells 56,213 Shares of Stock www.americanbankingnews.com - August 23 at 7:20 PM
	Regeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Morgan Stanley www.americanbankingnews.com - August 23 at 2:22 PM